510(k) SUMMARY AS REQUIRED BY SECTION 807.92(C)

Submitted by: Mrs. Mitsuko Yoneyama

President

Narishige Co., Ltd.

27-9, Minamikarasuyama 4-chome

Setagaya-ku Tokyo 157-0062

Japan

Phone: 81-3-3308-8383 Fax: 81-3-3308-8700

E-mail: sales@narishige.co.jp

Date Submitted: October 18, 2000

Device Identification:

Trade Name:

IM-5B Microinjector

Common Name:

Microinjector

Classification Name:

Assisted Reproduction Micromanipulators and

Microinjectors (21 CFR, 884.6150)

Predicate Device:

IM-9A Microinjector, Premarket Notification 510(k) Number: K001911

Device Description:

The IM-5B Microinjector is used to inject solutions into organisms, aspirate fluid samples from tissues or hold cells and eggs by aspiration onto the end of a holding pipette. It is easy to use simply by turning the Control Knob clockwise for injection and counterclockwise for aspiration.

The IM-5B Microinjector is a component part of a micromanipulator system. For ICSI procedure using the IM-5B, the micromanipulator system requires:

- 1 unit of the manipulator mounting adaptor (for mounting the micromanipulators to the microscope);
- 2 units of the coarse manipulator (for coarse positioning);
- 2 units of the fine micromanipulator (for fine positioning);
- 2 units of the joint unit (for holding the pipette holder)

K003303 Page 20f2

2 units of Microinjector (2 units of IM-5B Microinjector) (one for holding pipette and one for injecting pipette); 1 holding pipette;

and 1 injecting pipette.

Examples of roles the IM-5B plays in the ICSI would be:

- holding an oocyte

- aspirating a sperm into the injection pipette

- injecting a sperm into an oocyte

Intended Use:

The IM-5B Microinjector is used to inject solutions into organisms, aspirate fluid samples from tissues or hold cells and eggs by aspiration onto the end of a holding pipette.

Substantial Equivalence:

Narishige Co., Ltd. claims IM-5B Microinjector as substantially equivalent to Predicate IM-9A Microinjector, Premarket Notification 510(k) Number: K001911.

Technological Characteristic:

The IM-5B Microinjector is a manually operated screw-driven microinjector.

The specification of the IM-5B is summarized in the table below.

Maximum Movement Range of the Plunger		
The Distance the Plunger Travels by One Rotation of the	Approx.	
Control Knob	500μm	
The Amount Controlled by One Rotation of the Control Knob	Approx. 40µl	



NOV 2 2 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Mitsuko Yoneyama President Narishige Co., Ltd. 27-9, Minamikarasuyama 4-chome Setagaya-ku Tokyo 157-0062 JAPAN Re: K003303

IM-5B Microinjector Dated: October 18, 2000 Received: October 20, 2000

Regulatory Class: II

21 CFR §884.6150/Procode: 85 MQJ

Dear Ms. Yoneyama:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Daniel G. Schultz, M.D.

Captain, USPHS

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

		Page <u>1</u> of 1
510(k) Numl	ber (if known): K003303	en e
	e:	
Device Main	G	
Indications f The IM-5B samples fro pipette.	For Use: Microinjector is used to inject solutions i m tissues or hold cells and eggs by aspira	nto organisms, aspirate fluid tion onto the end of a holding
(PLEASE D NEEDED)	O NOT WRITE BELOW THIS LINE-CONT	TINUE ON ANOTHER PAGE IF
	Concurrence of CDRH, Office of Device	e Systuation (ODS)
943	Concurrence of Colvar, Office of Device	e Evaluation (ODE)
		(Optional Format 3-10-98)
	David a. Segery	

Prescription Use _____ (Per 21 CFR 801.109)